Brief: Advicenne Updates On ADV7103

Advicenne SA

26/05/2020 06:42

May 26 (Reuters) - ADVICENNE SA  ADVIC.PA :
    * SAID ON MONDAY IN EUROPE, REVIEW OF MARKETING APPLICATION
TO EMA
FOR ADV7103 IN THE TREATMENT OF DISTAL RENAL TUBULAR ACIDOSIS
(DRTA) PROCEEDS AS PLANNED, WITH AN ANTICIPATED POSITIVE OPINION
IN THIS FIRST INDICATION AT THE END OF 2020
    * OBJECTIVE FOR ADV7103 APPLICATION: TO OBTAIN EUROPEAN
UNION
APPROVAL FOR “DISTAL TUBULOPATHIES” INDICATION IN EARLY 2021
    * IN US, PIVOTAL PHASE II/III ARENA-2 CLINICAL TRIAL
EVALUATING
ADV7103 IN DRTA TREATMENT COULD NOT BE PURSUED DURING COVID-19
CRISIS, BUT IS EXPECTED TO RESUME IN FALL WITH A SIMPLIFIED
PROTOCOL

    
 Source text for Eikon:  ID:nBw9FPybRa 
    Further company coverage:  ADVIC.PA